Acute promyelocytic leukemia (APL) is the only AML subtype that can be effectively cured with retinoic acid and/or arsenic trioxide, in which functional promyelocytic leukemia-p53 axis-induced senescence is required to eradicate LSCs [6–8]. The gene discussed is TP53; the disease is acute promyelocytic leukemia.